
Stereotaxis Inc (STXS) Stock Forecast & Price Target
Stereotaxis Inc (STXS) Analyst Ratings
Bulls say
Stereotaxis Inc. is positioned for substantial financial growth, with forecasts indicating total revenue increasing to $43 million in FY26, representing a 24% rise, largely driven by new system sales and catheter utilization. The company reported a significant 95% year-over-year increase in revenue to $8.8 million for the second quarter, underscoring both strong demand for its existing Genesis system and the anticipated impact of the upcoming GenesisX launch. Furthermore, with a reaffirmed full-year 2025 guidance indicating continued double-digit revenue growth and substantial progress in regulatory approvals for multiple next-generation products, Stereotaxis is set to enhance its disposable revenue and overall market presence.
Bears say
Stereotaxis Inc. has reported a net loss of $3.8 million, with adjusted operating expenses decreasing to $6.0 million from $6.8 million in the prior year, indicating ongoing financial challenges despite some cost reductions. Key factors that could negatively impact the company's financial projections include delays in product approvals, supply issues with current catheters, and the potential for decreased reimbursement rates, all of which may hinder revenue growth. Additionally, the company faces significant competition from manual techniques and other robotic systems, along with a limited cash runway of two years that may necessitate seeking further financing to support operations and expand sales infrastructure.
This aggregate rating is based on analysts' research of Stereotaxis Inc and is not a guaranteed prediction by Public.com or investment advice.
Stereotaxis Inc (STXS) Analyst Forecast & Price Prediction
Start investing in Stereotaxis Inc (STXS)
Order type
Buy in
Order amount
Est. shares
0 shares